Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The study reported that from 2016 to 2020, the number of patients with alopecia areata in Taiwan increased, with severe cases utilizing more systemic therapies and having higher outpatient visits than mild/moderate cases.

This article discusses various types of alopecia more common in African-American individuals and reports no clinical results; it highlights the importance of recognizing and differentiating these subtypes for diagnosis and treatment.

This study found that patients with alopecia areata in Dubai experience significant disease and economic burdens, especially when comorbid with psychological conditions, despite frequent dermatologist consultations and topical steroid prescriptions.

This narrative review reports that Janus kinase inhibitors show promise as an effective treatment for alopecia areata, especially in patients who do not respond to conventional therapies, although further research on long-term use and topical application is needed.

This study found that severe forms of alopecia areata may be associated with poor treatment response, particularly in cases with extensive hair loss, juvenile onset, or nail changes.

This study highlights the genetic complexities in alopecia areata, emphasizing the role of microRNAs and their association with other immune-related diseases, which could inform targeted treatment strategies.

This case study reports the first known instance of successful rapid hair regrowth in a psoriasis patient with alopecia universalis after starting deucravacitinib, suggesting potential for TYK2 inhibitors in managing alopecia areata.

This consensus provides a framework for standardized diagnosis and treatment of alopecia areata in the Asia Pacific region, recommending specific therapies based on age and disease severity.

This case series found that topical janus kinase inhibitors, along with oral fexofenadine and vitamin D supplementation, significantly reduced disease severity in Black pediatric patients with alopecia areata, demonstrating substantial hair regrowth and minimal adverse side effects.

The researchers reported that baricitinib treatment for at least 52 weeks reduced severe alopecia areata severity and improved psychological well-being and quality of life in study participants.

In this case study, a 5-year-old girl with alopecia areata and atopic dermatitis that were unresponsive to previous treatments achieved substantial improvement with long-term tofacitinib, highlighting its potential safety and efficacy in managing both conditions concurrently.

In this study, topical and intralesional vitamin D3 and its analogs were found to be effective and safe treatments for mild-to-moderate alopecia areata, achieving a 53.75% success rate, though intralesional vitamin D3 was less effective than other treatments like corticosteroids.

This review, drawing on scientific literature, explores alopecia areata's pathogenesis and treatment, noting that while therapies like JAK inhibitors show promise, there remains a significant need for more effective and targeted solutions, and a better understanding of the disease mechanisms.

This study surveyed German dermatologists about treating children and adolescents with alopecia areata, revealing significant emotional challenges like bullying and low self-esteem, dissatisfaction with available treatments, and a need for both psychological support and new therapeutic guidelines.

This study reported that both 5% topical and oral minoxidil achieved an 82% hair regrowth response rate in alopecia areata patients, but 5% topical minoxidil was more effective than lower concentrations.

This review highlights that alopecia areata, a common type of hair loss, currently lacks preventive or curative treatments, and traditional therapies such as minoxidil and corticosteroids offer inconsistent results, necessitating patient-consensual treatment planning.

This review discusses the pathophysiology, economic burden, and treatment options of alopecia areata and reports no new clinical results, highlighting the need for better therapies, including JAK inhibitors.

This article discusses the clinical features of tumid lupus erythematosus and emphasizes its importance as a differential diagnosis for noncicatricial alopecia, highlighting a case similar to alopecia areata without reporting new clinical results.

This study reported that in a case series of three adolescents with alopecia areata and atopic dermatitis, treatment with 15 mg/day of upadacitinib led to rapid improvement in skin symptoms and significant hair regrowth over 12 months, with no severe adverse events observed.

This study developed a simplified multidimensional assessment scale for alopecia areata severity and systemic treatment initiation among Chinese patients, achieving expert consensus on relevant clinical indicators and conditions.

In this study, a patient with severe alopecia areata showed significant hair regrowth after 15 months of partial response to baricitinib and oral minoxidil, following the addition of dupilumab to their treatment regimen.

This study reviewed 562 alopecia areata patients in Colombia, observing a higher prevalence in women and common use of steroid injections and topical minoxidil as treatments.

This study found that platelet-rich plasma was more effective for treating alopecia areata than topical 5% minoxidil, leading to earlier hair regrowth and reduction in hair abnormalities.

This study found that 1,540 nm fractional erbium-glass laser treatment combined with topical minoxidil significantly increased hair regrowth in alopecia areata patches compared to minoxidil alone, with response rates of 60% versus 16%, though the long-term effects remain unknown.

This paper reviews alopecia areata incognita, a condition causing diffuse hair loss without typical patches, and highlights the need for scalp biopsy for diagnosis, but reports no new findings.

In this study, using a combination of topical minoxidil (2%) and isotretinoin (0.05%) gel led to complete hair regrowth in 83.3% of alopecia areata patients within six months, demonstrating effective and well-tolerated treatment results.

This review discusses common skin conditions in primary care settings and provides guidance on differential diagnoses and selecting appropriate topical treatments, but it reports no new clinical results.

In this study, two patients with localized hair thinning showed histopathological signs typical of alopecia areata, responding to corticosteroid treatment similarly to classical cases.

This study suggests that while vitamin D3 deficiency is linked to alopecia areata severity, evidence for the effectiveness of supplementation or topical calcipotriol treatment remains inconsistent and low quality.

In this case study, an 11-year-old boy with extensive alopecia areata showed 80% hair regrowth after six months of treatment with methylprednisolone despite initial lack of response to topical therapies.